Systems and Methods for Anti-SOX10 Antibodies

• US 20180074065A1
• Filed: 11/13/2017
• Published: 03/15/2018
• Est. Priority Date: 10/03/2013
• Status: Active Grant

• Current Assignee: Biocare Medical LLC
• Original Assignee: Biocare Medical LLC
• Inventors: Tacha, David, Qi, Weimin
• Granted Patent: US 10,295,542 B2
• Time in Patent Office: Days
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/3053 Skin, nerves, brain
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 33/57496 involving intracellular compounds

Abstract

The present invention is related to the anti-SOX10 antibodies, kits, cocktails, and use of anti-SOX10 antibodies for detection of cancer.

Claims

1-112. -112. (canceled)

113. A composition comprising a first antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under ATCC Patent Deposit Designation No. PTA-120969 and at least one other antibody or fragment thereof.

114. The composition of claim 113 wherein said at least one other antibody or fragment thereof binds specifically to a protein selected from a group consisting of:

MART-1, Melan A, and Tyrosinase.

115. The composition of claim 113 wherein said first antibody and said at least one other antibody or fragment thereof bind specifically to proteins selected from a group consisting of:

SOX10 and MART-1;

SOX10 and Tyrosinase;

SOX10 and MART-1 and Tyrosinase;

SOX10 and Melan A; and

SOX10 and Melan A and Tyrosinase.

116. The composition of claim 113 wherein said first antibody and at least one other antibody comprise monoclonal antibodies.

117. The composition of claim 113 wherein said first antibody and at least one other antibody comprise mouse antibodies.

118. The composition of claim 113 wherein said at least one other antibody or fragment thereof is derived from a different species than said first antibody.

119. The composition of claim 113 wherein said at least one other antibody or fragment thereof is derived from a species selected from the group consisting of rabbit, goat, horse, chicken, and human.

120. The composition of claim 113 further comprising a label attached to said first antibody and said at least one other antibody or fragment thereof.

121. The composition of claim 120 wherein said label is selected from the group consisting of a radioactive element, magnetic particles, radioisotope, fluorescent dye, enzyme, toxin, signal, stain, detection enzymes, horseradish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase, chromogens, 3,3′

-diaminobenzidine, 3-amino-9-ethylcarbazole, 5-bromo-4-chloro-3-indolyl phosphate, 3,3′

,5,5′

-tetramethylbenzidine, 5-bromo-4-chloro-3-indolyl-β

-D-glucuronide, and any combination thereof.

122. A method for detecting, in a biological sample, a protein to which said first and said at least one other antibody of claim 113 binds;

comprising the steps of contacting said biological sample with said antibodies of claim 113 and detecting the presence of said antibody bound to the protein in a biological sample.

123. The method of claim 122 wherein said biological sample comprises lung tissue, bladder tissue, breast tissue, or prostate tissue.

124. The method of claim 122 wherein said biological sample is selected from the group consisting of a normal tissue, neoplastic tissue, bladder tissue, kidney tissue, ovarian tissue, thyroid tissue, endometrial tissue, renal tissue, tonsil tissue, pancreas tissue, colon tissue, lymph node tissue, neoplastic pancreatic tissue, stomach tissue, prostate tissue, lung tissue, skin tissue, and breast tissue.

125. The method of claim 122 wherein said detecting said presence of said antibody bound to the protein is performed on an automated staining device.

126. The method of claim 122 wherein said detecting said presence of said antibody bound to the protein is selected from the group consisting of:

manually detecting, automatically detecting, and image analysis.

127. The method of claim 122 wherein said detecting said presence of said antibody bound to the protein in said biological sample comprises a method selected from the group consisting of immunohistochemistry (IHC), IHC of formalin fixed paraffin embedded (FFPE) tissue, IHC of frozen tissue sections, immunocytochemistry, and ELISA.

128. The method of claim 122 wherein said biological sample comprises tissue;

and

wherein the method further comprises the steps of;

fixing or freezing said tissue; and

treating said fixed or frozen tissue to unmask epitopes to Sry-related HMG-Box gene 10 protein (SOX10).